These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 6704976)

  • 1. Pharmacological evaluation of intravenous delivery of 5-bromodeoxyuridine to patients with brain tumors.
    Russo A; Gianni L; Kinsella TJ; Klecker RW; Jenkins J; Rowland J; Glatstein E; Mitchell JB; Collins J; Myers C
    Cancer Res; 1984 Apr; 44(4):1702-5. PubMed ID: 6704976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical pharmacology of hepatic arterial infusions of 5-bromo-2'-deoxyuridine.
    Ensminger WD; Walker SC; Stetson PL; Wagner JG; Knol JA; Lawrence TS; Andrews JC
    Cancer Res; 1994 Apr; 54(8):2121-4. PubMed ID: 8174116
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of intraarterial mitomycin C in humans.
    Hu E; Howell SB
    Cancer Res; 1983 Sep; 43(9):4474-7. PubMed ID: 6409404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor radiosensitization by sustained intratumoral release of bromodeoxyuridine.
    Doiron A; Yapp DT; Olivares M; Zhu JX; Lehnert S
    Cancer Res; 1999 Aug; 59(15):3677-81. PubMed ID: 10446981
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regional pharmacokinetics of 5-bromo-2'-deoxyuridine and 5-fluorouracil in dogs: hepatic arterial versus portal venous infusions.
    Kuan HY; Smith DE; Ensmiger WD; Knol JA; DeRemer SJ; Yang Z; Stetson PL
    Cancer Res; 1996 Oct; 56(20):4724-7. PubMed ID: 8840990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced systemic drug exposure by combining intraarterial cis-diamminedichloroplatinum(II) with hemodialysis of regional venous drainage.
    Oldfield EH; Clark WC; Dedrick RL; Egorin MJ; Austin HA; DeVroom HD; Joyce KM; Doppman JL
    Cancer Res; 1987 Apr; 47(7):1962-7. PubMed ID: 3815385
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutual kinetic interaction between 5-fluorouracil and bromodeoxyuridine or iododeoxyuridine in dogs.
    Smith DE; Brenner DE; Knutsen CA; Deremer SJ; Terrio PA; Johnson NJ; Stetson PL; Ensminger WD
    Drug Metab Dispos; 1993; 21(2):277-83. PubMed ID: 8097697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bromodeoxyuridine-mediated radiosensitization in human glioma: the effect of concentration, duration, and fluoropyrimidine modulation.
    McLaughlin PW; Lawrence TS; Seabury H; Nguyen N; Stetson PL; Greenberg HS; Mancini WR
    Int J Radiat Oncol Biol Phys; 1994 Oct; 30(3):601-7. PubMed ID: 7928491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I study of intracarotid artery infusion of cis-Diamminedichloroplatinum(II) in patients with recurrent malignant intracerebral tumors.
    Stewart DJ; Wallace S; Feun L; Leavens M; Young SE; Handel S; Mavligit G; Benjamin RS
    Cancer Res; 1982 May; 42(5):2059-62. PubMed ID: 7199971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical pharmacology of intraarterial cis-diamminedichloroplatinum(II).
    Stewart DJ; Benjamin RS; Zimmerman S; Caprioli RM; Wallace S; Chuang V; Calvo D; Samuels M; Bonura J; Loo TL
    Cancer Res; 1983 Feb; 43(2):917-20. PubMed ID: 6681533
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incorporation of 5-bromo-2'-deoxyuridine into colorectal liver metastases and liver in patients receiving a 7-day hepatic arterial infusion.
    Knol JA; Walker SC; Robertson JM; Yang Z; DeRemer S; Stetson PL; Ensminger WD; Lawrence TS
    Cancer Res; 1995 Sep; 55(17):3687-91. PubMed ID: 7641176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary central nervous system lymphoma: Phase I evaluation of infusional bromodeoxyuridine with whole brain accelerated fractionation radiation therapy after chemotherapy.
    Dabaja BS; McLaughlin P; Ha CS; Pro B; Meyers CA; Seabrooke LF; Wilder RB; Kyritsis AP; Preti HA; Yung WK; Levin V; Cabanillas F; Cox JD
    Cancer; 2003 Sep; 98(5):1021-8. PubMed ID: 12942571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Phase I study of intermittent intravenous bromodeoxyuridine (BUdR) with conventional fractionated irradiation.
    Kinsella TJ; Russo A; Mitchell JB; Rowland J; Jenkins J; Schwade J; Myers CE; Collins JM; Speyer J; Kornblith P
    Int J Radiat Oncol Biol Phys; 1984 Jan; 10(1):69-76. PubMed ID: 6321412
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intra-arterial bromodeoxyuridine radiosensitization and radiation in treatment of malignant astrocytomas.
    Greenberg HS; Chandler WF; Diaz RF; Ensminger WD; Junck L; Page MA; Gebarski SS; McKeever P; Hood TW; Stetson PL
    J Neurosurg; 1988 Oct; 69(4):500-5. PubMed ID: 3047341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II evaluation of topotecan for pediatric central nervous system tumors.
    Blaney SM; Phillips PC; Packer RJ; Heideman RL; Berg SL; Adamson PC; Allen JC; Sallan SE; Jakacki RI; Lange BJ; Reaman GH; Horowitz ME; Poplack DG; Balis FM
    Cancer; 1996 Aug; 78(3):527-31. PubMed ID: 8697400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kinetics of bromodeoxyuridine elimination from human colon cancer cells in vitro and in vivo.
    Lawrence TS; Davis MA; Stetson PL; Maybaum J; Ensminger WD
    Cancer Res; 1994 Jun; 54(11):2964-8. PubMed ID: 8187082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of intracranial rat glioma model with implant of radiosensitizer and biomodulator drug combined with external beam radiotherapy.
    Li Y; Owusu A; Lehnert S
    Int J Radiat Oncol Biol Phys; 2004 Feb; 58(2):519-27. PubMed ID: 14751523
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
    Supko JG; Eder JP; Ryan DP; Seiden MV; Lynch TJ; Amrein PC; Kufe DW; Clark JW
    Clin Cancer Res; 2003 Nov; 9(14):5178-86. PubMed ID: 14613997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical trial of intravenous infusion of bromodeoxyuridine (BUdR) for radiosensitization of malignant brain tumors.
    Matsutani M; Kohno T; Nagashima T; Nagayama I; Matsuda T; Hoshino T; Sano K
    Radiat Med; 1988; 6(1):33-9. PubMed ID: 3045898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I study of high-dose tamoxifen for the treatment of refractory malignant gliomas of childhood.
    Pollack IF; DaRosso RC; Robertson PL; Jakacki RL; Mirro JR; Blatt J; Nicholson S; Packer RJ; Allen JC; Cisneros A; Jordan VC
    Clin Cancer Res; 1997 Jul; 3(7):1109-15. PubMed ID: 9815790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.